HONG KONG, May 29, 2025 - (ACN Newswire via SeaPRwire.com) – MODONG Coffee, a leading global health and wellness brand, is proud to announce its sponsorship of G-DRAGON 2025 WORLD TOUR [Übermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP, taking place on July 11 (Fri.) and July 13 (Sun.) at the Taipei Arena. As the Official Sponsor, MODONG Coffee brings an innovative fusion of “Music × MODONG Energy” to create an immersive audiovisual experience for fans. This collaboration marks a strategic milestone in MODONG Coffee’s youth-centric expansion, advancing its “IP + Scenarios + New Retail” ecosystem.As one of Asia's most influential music IPs, G-DRAGON’s upcoming tour, themed "Übermensch", symbolizes his groundbreaking interpretation of art and self-expression. As an Official Sponsor, MODONG Coffee joins forces with Samsung, ADATA Technology, and other brands to deliver an immersive experience, seamlessly blending stunning visuals with exceptional music for the audience. As the flagship product of Star Plus Legend's new retail business, MODONG Coffee has established a leading position in China’s bulletproof drink market since its launch in 2019 with its differentiated product positioning. According to China Insights Consultancy, MODONG coffee has ranked first in the bulletproof drink market by GMV in the PRC for five consecutive years (2020-2024). As of 2024, the cumulative sales of MODONG coffee have reached 100 million cups. That same year, MODONG brand and its products earned multiple prestigious certifications, including “a high profile brand in Jiangsu province” and “the iSEE list of top 100 innovative brands”, further solidifying its market competitiveness.Additionally, MODONG Coffee has deeply integrated with the phenomenal variety show IP "J-Style Trip", achieving "traffic-to-sales conversion" through celebrity-driven marketing and scenario-based campaigns. This strategy drove a 360% year-on-year sales surge in its debut year, propelling Star Plus Legend’s net profit to soar 233% YoY. To meet evolving consumer demands, MODONG Coffee underwent a brand upgrade in 2025, launching the MODONG MAGIC series—Sicilian Lemon Coffee and Cactus Black Coffee—under the concept "A Cup On-the-Go: Crafting Magic for Healthy Living". The brand aims to pioneer a new MODONG lifestyle rooted in low-carb diets and scientific fitness, fostering healthier habits and redefining the relationship between nutrition and wellness. To amplify brand influence, MODONG MAGIC became the exclusive title sponsor of "J-Style Trip Season 3". The show has aired nine episodes to date, dominating CSM71-city provincial satellite TV ratings with nine consecutive time-slot No.1 rankings. It generated 298 trending topics and over 2.9 billion impressions across platforms, igniting widespread social engagement. The support for the "G-DRAGON 2025 WORLD TOUR [Übermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP" represents a key step in MODONG Coffee’s strategic layout of combining “healthy trendy beverages + entertainment.” By leveraging G-DRAGON's global fan appeal and the high popularity of the concert, the brand aims to further expand its influence in the Asia-Pacific market — marking a significant leap for MODONG Coffee from product to brand, and from local to global.Looking ahead, MODONG will remain sharply focused on Gen Z consumers, engaging them through health, music, fashion, and digital art to strengthen its youth-oriented identity. Powered by AI-driven IP innovation, the brand is poised to accelerate the fusion of digital technology and the real economy. Copyright 2025 ACN Newswire via SeaPRwire.com.

Key Highlights- Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy- Globally, this is the first bispecific CD19-directed CD3 T cell engager immunotherapy for this autoimmune disease- Milder T cell activation than Blincyto and Target cell-dependent T cell activation- Multiple CR cases observed in ongoing r/r NHL Phase Ia trial and r/r ALL Phase Ib/II trialHONG KONG, May 29, 2025 - (ACN Newswire via SeaPRwire.com) – Excyte, a global clinical-stage biotechnology company, announced first patient has been dosed for YK012, the world’s first patient T cell engager that entered into clinical trial for primary membranous nephropathy (pMN). The patient remained well after administration with no adverse reactions witnessed to date.pMN is an autoimmune disease caused by the attack of autoantibodies against podocyte antigens leading to the in situ production of immune complexes. pMN is the most common cause of primary nephrotic syndrome in non-diabetic adults worldwide, accounting for 20% to 37% of affected individuals, and as high as 40% in adults over 60 years of age (1). Currently, 20-30% of pMN cases are resistant to current therapies like rituximab and cyclophosphamide and relapse rates can be high (2).A clear regulatory pathway in this orphan disease in US could make YK012 one of the first approved TCE in the autoimmune space with many other autoimmune and oncology indications to follow. Excyte would file for US investigational new drug (IND) application imminently.The study aims to evaluate the safety, tolerability, and preliminary efficacy of YK012 in PMN patients. Led by Professor Minghui Zhao and Prof Zhao Cui from Peking University First Hospital, the trial is planned to be conducted across multiple centers in China. The clinical trial for this indication in the United States will be collaboratively executed by Excyte and its international partners.“YK012 is a T-cell engaging bispecific antibody targeting both CD19 and CD3, activating T-cell immunity via CD3 while targeting CD19—the most widely expressed tissue-specific marker during B-cell development and thereby enabling B-cell reset. Our data illustrated YK012 mediated significant B cell depletion and have illustrated in current clinical studies extended half-life and limited cytokine release in patients,” said Mr. Andrew Meng, chairman and COO at Excyte. “We look forward to collaborating with regulatory authorities to make YK012 available to this patient population with a high unmet medical need."In December 2024, YK012 obtained Clinical Trial Approval Notice (No. CXSL2400727) from China's National Medical Products Administration (NMPA) and was registered on ClinicalTrials.gov (NCT06982729). With the first patient dosed in pMN, Excyte now has a global presence in autoimmune diseases in additional to oncology indications such as NHL and ALL. Earlier this year, Excyte also secured clinical trial approval for systemic lupus erythematosus (SLE), with Professor Xiaofeng Zeng from Peking Union Medical College Hospital serving as Principal Investigator.About Excyte Biopharma Ltd.Excyte Ltd. was co-founded by Dr Qing’an Yuan and Mr Andrew Meng , biotech industry veterans with decades of antibody engineering experiences. The company has also established a U.S.-based wholly-owned subsidiary, Excyte LLC, forming a dual-engine drug R&D hub spanning China and the U.S. Excyte is dedicated to developing innovative bispecific antibody drugs for hematologic cancers, multiple myeloma, solid tumors, autoimmune diseases, and other conditions. Excyte’s FIST platform and next generation assets possess features such as long-acting, low-toxicity, and high-yield technological innovations. For more information, please visit https://www.iExcyte.com/Business Development ContactYing Liu, liuying@iExcyte.comReferences:1.William G Couser, Primary Membranous Nephropathy, Clin J Am Soc Nephrol. 2017 May 26;12(6):983–997.2.Elham Ahmadian, Seyed Mahdi Hosseiniyan Khatibi, Sepideh Zununi Vahed, Mohammadreza Ardalan, Novel treatment options in rituximab-resistant membranous nephropathy patients, International Immunopharmacology, Volume 107, 2022, 108635, ISSN 1567-5769. Copyright 2025 ACN Newswire via SeaPRwire.com.

BANGKOK, May 28, 2025 - (ACN Newswire via SeaPRwire.com) - Sappe PCL (SAPPE), a pioneer in beverage innovation from Thailand that has gained recognition among consumers worldwide, is set to reinforce its global brand ambition at THAIFEX – ANUGA ASIA 2025, Asia’s premier food and beverage trade exhibition. The event will take place from May 27–31, 2025, at Booth 1-QQ01, Impact Challenger Hall 1, Muang Thong Thani, Bangkok, Thailand.The highlight of this year’s showcase is the official launch of Mogu Mogu’s new global campaign, “Life’s too Short, You Gotta Chew” presenting the world’s first Snackable Drink, a category created by SAPPE itself. The campaign marks a major milestone in reshaping the global beverage experience by blending taste, texture, and lifestyle in one fun and refreshing product.Mission to Mars: A Thai Brand Journey to the Future of Global GrowthUnder the concept of “Mission to Mars,” SAPPE’s exhibition booth is designed to resemble a spacecraft transporting over 10 beverage brands from Thailand on a journey into the future. The concept symbolizes bold creativity, forward thinking, and the ambition to share Thai-made innovations with consumers worldwide.Featured products include Mogu Mogu, Sappe Aloe Vera, Sappe Beauti, and the company’s newest innovations designed with a strong focus on quality, taste, functionality, health benefits, and environmental responsibility, to meet the evolving preferences of today’s global consumers.Mogu Mogu: Turning Ordinary Days into Chewable FunThe “Life’s too Short, You Gotta Chew” campaign makes its global debut at the event, supported by three vibrant new TV commercials. The campaign highlights Mogu Mogu’s playful, upbeat personality and connects with today’s young consumers who seek Social Connection, FOMO (Fear of Missing Out), Instant Gratification, and a lifestyle filled with fun and spontaneity.SAPPE is working with key partners in major international markets including South Korea, Philippines, France, and the United Kingdom to expand the campaign’s global reach and deepen engagement with Mogu Mogu’s growing fan base. The company aims to significantly increase international brand engagement by the end of this year.Beyond Export: SAPPE’s Vision to Build a Lasting Global BrandMs. Piyajit Rackariyapong, Chief Executive Officer of SAPPE, said:“We don’t just export beverages. Our mission is to build a brand from Thailand that leads with innovation, offers new excitement and drinking experiences to consumers, and brings positivity into people’s everyday lives.”SAPPE’s consistent participation in THAIFEX – ANUGA ASIA for over a decade reflects the company’s commitment to becoming a creative force in the global beverage industry driven by bold ideas, cultural connection, and consumer empathy.THAIFEX – ANUGA ASIA: A Global Value Chain GatewayOrganized by Thailand’s Department of International Trade Promotion (DITP) in partnership with the Thai Chamber of Commerce and Koelnmesse Germany, THAIFEX – ANUGA ASIA serves as a critical platform for Asian food and beverage brands to connect with the global value chain. SAPPE continues to be one of the most prominent Thai brands recognized annually on this stage.Visit SAPPE at Booth 1-QQ01, IMPACT Challenger Hall 1, Muang Thong Thani, Bangkok, Thailand, throughout the 5-day event. Follow Mogu Mogu’s global journey at www.mogumogu.comAbout SAPPESappe Public Company Limited (SAPPE) is a leading Thai beverage innovator and the owner of several iconic brands. The company specializes in fruit juice and functional drinks, developed to serve the modern lifestyle of consumers across global markets. SAPPE currently exports to over 100 countries worldwide, with a strong presence in Asia, Europe, and the Middle East.Its portfolio includes globally recognized brands such as Mogu Mogu, the world’s first Snackable Drink; Sappe Aloe Vera, known for its refreshing taste and natural ingredients; and Sappe Beauti, a health-focused functional drink line. SAPPE is headquartered in Bangkok, Thailand, and is listed on the Stock Exchange of Thailand (SET) under the symbol SAPPE.Driven by innovation, consumer insights, and sustainability, SAPPE is committed to delivering high-quality products that bring joy, well-being, and new experiences to people around the world.Sappe official: https://www.sappe.com/en/Facebook: https://www.facebook.com/sappeplaygroundInstagram: https://www.instagram.com/mogumogu_global/Line: https://shop.line.me/@sappeonlineShopee: https://shopee.co.th/sappe.officialEmail: corpcom@sappe.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, May 28, 2025 - (ACN Newswire via SeaPRwire.com) – Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic devices provider, announced the successful launch of the 30th Anniversary Celebration and Symposium “Hexallence Beyond 30: Pioneering Tomorrow’s Dentistry” by its Thai subsidiary Hexa Ceram Dental Laboratory (“Hexa Ceram”) in Bangkok, Thailand on 24th May. As a crucial segment of Modern Dental Group's strategic framework in the Asia-Pacific region, Hexa Ceram's 30th anniversary celebration is not only a milestone for the industry but also marks a new starting point for the collaborative development of both parties.In the 30 years since its establishment in 1995, Hexa Ceram has been committed to promoting innovation in dental technology. By 2023, its local market share reached 29%, making it the top dental laboratory in Thailand. It has become a benchmark company in the dental field in Thailand and Southeast Asia. Themed "Pioneering Tomorrow’s Dentistry", this year's celebration aims to review the technological advancements and industry contributions of the brand over the past 30 years, and to open up a forward-looking vision in dentistry for practitioners through insightful discussions with top-tier scholars globally. The symposium specially invited 300 dentists, 100 VIP customers in the industry, dean from 10 top universities and presidents of dental associations to jointly build a blueprint for the future development of dentistry. At this new milestone, Hexa Ceram is dedicated to delivering high-quality and innovative dental solutions and services continuously. It is committed to expanding the presence in the ASEAN Economic Community, fostering growth and excellence in dental care.The global dental industry is currently undergoing an accelerated transformation from traditional models to precision-driven and intelligent approaches. With Hexa Ceram officially incorporated into the global system of Modern Dental Group, the two parties will continue to strengthen their leadership in the Thai market through technological innovation, resource synergy and integration, and effectively promote the Group's competitiveness in the global dental industry value chain. Looking ahead, the Group will continue to maintain its focus on digital innovation as a catalyst and give full play to the strategic role of Hexa Ceram to build a dental ecosystem network in Southeast Asia. Through international technology integration, service model advancements and global resource collaboration, we strive to elevate oral diagnosis and treatment technology in Southeast Asia and globally, delivering transformative dental solutions.About Modern Dental Group Modern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices.Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, and Apex Digital Dental in Malaysia. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 30,000 customers. Copyright 2025 ACN Newswire via SeaPRwire.com.

Highlights Financing included an upsized C$9.8 million (A$10.8 million) Private Placement and an oversubscribed A$1.5 million (C$1.4 million) Share Purchase PlanCompany welcomes the European Bank of Reconstruction and Development and Eric Sprott as significant shareholdersFunds raised to support ongoing development of the Chvaletice Manganese Project and customer engagements to secure additional offtake term sheets and strategic investmentsVancouver, British Columbia--(ACN Newswire via SeaPRwire.com - May 28, 2025) - Euro Manganese Inc. (TSXV) (ASX: EMN) (FSE: E060) (the "Company" or "Euro Manganese") is pleased to announce that, following the approval by its shareholders at its Annual General and Special Meeting held on May 15, 2025 (the "AGSM"), it has closed the previously announced financing package which included: (a) a private placement (the "Placement") of common shares ("New Shares") and CHESS Depositary Interests ("New CDIs" together with the New Shares, "New Securities") in the capital of the Company of C$9.8 million (approximately A$10.8 million); and (b) a Share Purchase Plan ("SPP", together with the Placement, the "Financing") with certain eligible shareholders in the amount of A$1.5 million (approximately C$1.4 million). The Company also announces an option grant to certain directors, officers, employees, and consultants as described below.Martina Blahova, CEO of Euro Manganese, commented:"We are extremely pleased with the strong support demonstrated by both our existing shareholders and new investors, including the notable participation of Mr. Eric Sprott. As Euro Manganese's largest shareholder, EBRD's investment reinforces its support and commitment to the Chvaletice Project. This critical financing enables the Company to pursue certain key milestones and advance project development. We thank shareholders for their ongoing support."The net proceeds of the Financing will be used to support ongoing development of the Chvaletice Manganese Project, including customer engagements to secure additional offtake term sheets and strategic investments, the operation of the demonstration plant, as needed, to market the Company's product to potential customers and to advance permitting.All defined terms in this press release have the same meaning as set out in the press releases dated March 6, 2025 and April 1, 2025, unless such terms are otherwise defined herein.Details of the PlacementThe Placement consisted of the issuance of an aggregate of 54,578,350 New Securities, comprised of 39,671,662 New Shares at a price of C$0.18 per New Share and 14,906,688 New CDIs (with each New CDI representing one New Share) at a price of A$0.195 per New CDI, and 54,578,350 Warrants for aggregate gross proceeds of C$9.8 million (approximately A$10.8 million). Warrants issued in connection with the Placement are exercisable any time prior to November 28, 2026 (Vancouver), and have an exercise price of C$0.225 per New Security. Included in the Placement were:14,650,278 New CDIs and 14,650,278 Warrants subscribed for under the Placement led by the Joint Lead Managers (as defined below);39,463,331 New Shares and 39,463,331 Warrants subscribed for directly with the Company, which included (i) 21,400,000 New Shares and 21,400,000 Warrants subscribed for by the European Bank for Reconstruction and Development ("EBRD") (the "EBRD Subscription"); (ii) 16,666,666 New Shares and 16,666,666 Warrants subscribed for by Mr. Eric Sprott, through 2176423 Ontario Ltd., a corporation which is beneficially owned by Mr. Sprott; and (iii) 1,396,665 New Shares and 1,396,666 Warrants subscribed for by other, non-related investors; andsubscriptions by directors of the Company for 464,741 New Securities (comprised of 208,331 New Shares and 256,410 New CDIs) and 464,741 Warrants (the "Related Party Subscription").As the number of New Securities and Warrants issued under the Placement led by the Joint Lead Managers, pursuant to the EBRD Subscription, and subscribed for directly with the Company exceeded the number of securities permitted to be issued without obtaining prior shareholder approval under Listing Rule 7.1 of the Australian Securities Exchange ("ASX"), the Company was required to seek shareholder approval. Similarly, the Related Party Subscriptions were subject to shareholder approval as required by ASX Listing Rule 10.11.1 and 10.11.4. Resolutions approving these issues were sought and received at the AGSM.Since certain directors and management of the Company participated in the Placement, the Placement is considered to be a related party transaction subject to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(a) and 5.7(1)(a) of MI 61-101 on the basis that participation in the Placement by such directors and management does not exceed 25% of the fair market value of the Company's market capitalization, as calculated in accordance with MI 61-101.Details of the Share Purchase PlanThe SPP was conducted pursuant to a Prospectus dated April 23, 2025 and was comprised of 7,692,307 New CDIs at a price of A$0.195 per CDI, and 7,692,307 Warrants, for aggregate gross proceeds of A$1.5 million (approximately C$1.4 million). Warrants issued in connection with the SPP are exercisable any time prior to November 28, 2026 (Vancouver), with an exercise price of C$0.225 per New Security.As announced in the Company's news release of May 15, 2025, the SPP was oversubscribed and subscriptions were scaled back to the maximum aggregate amount permitted.As the number of New CDIs and Warrants issued under the SPP exceeded the Company's Placement Capacity under ASX Listing Rule 7.1, the Company was required to seek shareholder approval, such approval having been received at the AGSM.Broker Fees and Additional WarrantsCanaccord Genuity (Australia) Limited ("Canaccord Genuity") and Foster Stockbroking Pty Ltd ("FSB", together with Canaccord Genuity, the "Joint Lead Managers") acted as Joint Lead Managers and Bookrunners for the Financing. Aggregate fees payable in cash by the Company to Canaccord Genuity and FSB in connection with the Financing consisted of A$498,918 (approximately C$454,016).In addition, the Company also issued 4,904,478 broker warrants (the "Broker Warrants") to Canaccord Genuity and FSB, representing 12% of the aggregate number of New Securities issued under the Placement and the SPP, excluding those issued pursuant to the EBRD Subscription. The Broker Warrants are exercisable any time prior to May 28, 2027 (Vancouver), with an exercise price of C$0.225 per New Security.Additionally, as announced previously on March 6, 2025 and April 1, 2025, and in connection with an amendment to the Company's Convertible Loan Royalty Agreement (the "CLRA") with OMRF (BK) LLC ("Orion") the Company has issued 22,263,733 warrants to purchase New Securities (the "Additional Warrants") to Orion, exercisable any time prior to November 28, 2026 (Vancouver), with an exercise price of C$0.225 per New Security. Additional details about the CLRA are available in the news releases of the Company dated December 3, 2024, November 29, 2023 and November 27, 2023.As the number of the Broker Warrants and Additional Warrants exceeded the Company's Placement Capacity under ASX Listing Rule 7.1, the Company was required to seek shareholder approval, such approvals having been received at the AGSM.Applicable Hold PeriodsNew Shares issued or made issuable under the Financing will not be permitted to be traded in or into Canada or through the facilities of the TSX Venture Exchange (the "TSX-V") prior to a four month and one day statutory hold period expiring on September 29, 2025 (Vancouver), and will be subject to legending requirements under Canadian securities laws. New Shares will be listed on the TSX-V and New CDIs listed on the ASX. The Warrants, Broker Warrants and Additional Warrants will not be listed. New CDIs will not be permitted to be exchanged for common shares and traded through the facilities of the TSX-V prior to the four month and one day statutory hold period expiring on September 29, 2025 (Vancouver).The Warrants, Broker Warrants and Additional Warrants will not be listed. Common shares issued upon exercise of the Warrants, Broker Warrants or Additional Warrants prior to September 29, 2025 (Vancouver) are subject to the same restrictions noted above.The Warrants, Broker Warrants or Additional Warrants may not be traded in or into Canada prior to September 29, 2025 (Vancouver) and will be subject to legending requirements under Canadian securities laws.Early Warning Disclosure for The European Bank for Reconstruction and DevelopmentEBRD acquired the 21,400,000 units pursuant to the Placement at a price per unit of C$0.18 for total consideration of C$3,852,000.Prior to the completion of the EBRD Subscription, EBRD owned 3,560,000 common shares, representing an ownership interest of 4.42% of the issued and outstanding common shares of the Company. On completion of the EBRD Subscription, EBRD's ownership interest increased to 24,960,000 common shares, representing an ownership interest of 17.48% of the issued and outstanding common shares and an increase of 13.06%. Assuming the exercise by EBRD of all its Warrants, and assuming the exercise of (i) all Warrants issued under the Placement, (ii) all Warrants issued under the SPP, and (iii) all Additional Warrants, EBRD's ownership interest will be in aggregate 46,360,000 common shares, representing an aggregate beneficial ownership interest of 19.96% of the issued and outstanding shares and an increase of 15.54%. EBRD has agreed, pursuant to the terms of the Warrants issued to EBRD, that for so long as the Company is listed on the TSX-V, unless approval from the TSX-V and disinterested shareholders of the Company have been obtained pursuant to the policies of the TSX-V (provided that such approval is required at the relevant time), EBRD will not be permitted to exercise such number of warrants that would result in it beneficially owning more than 19.99% of the outstanding common shares of the Company.EBRD acquired the New Shares and Warrants for investment purposes. Depending on market conditions and other factors, EBRD may from time to time acquire and/or dispose of securities of the Company or continue to hold its current position.To obtain a copy of the early warning report to be filed by EBRD in connection with this press release, please contact: Michael Zlobin at +44 207338 8981. EBRD's address is 5 Bank Street, London, E14 4BG, United Kingdom.Early Warning Disclosure for Eric SprottEric Sprott, through 2176423 Ontario Ltd., a corporation that is beneficially owned by him acquired 16,666,666 units pursuant to the Placement, at $0.18 per unit for total consideration of C$3,000,000. Prior to the Placement, Mr. Sprott did not beneficially own or control any securities of the Company. As a result of the Placement, Mr. Sprott now beneficially owns 16,666,666 Shares and 16,666,666 Warrants, representing approximately 11.7% of the outstanding Shares on a non-diluted basis and 20.9% of the outstanding Shares on a partially-diluted basis assuming exercise of such Warrants.The securities are held for investment purposes. Mr. Sprott has a long-term view of the investment and may acquire additional securities including on the open market or through private acquisitions or sell the securities including on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.A copy of the early warning report with respect to the foregoing will appear on Euro Manganese's profile on SEDAR+ at www.sedarplus.ca and may also be obtained by calling Mr. Sprott's office at (416) 945-3294 (2176423 Ontario Ltd., 7 King Street East, Suite 1106, Toronto Ontario M5C 3C5).Option GrantThe Company today also granted stock options ("Options") to certain of its directors, officers, employees, and consultants to purchase up to an aggregate of 7,020,000 common shares ("Shares"). Of these, 1,330,000 Options have been granted to directors, 2,530,000 Options have been granted to officers, and 3,160,000 Options have been granted to employees and consultants. The Options are exercisable for a term of ten years at an exercise price of CAD$0.19 per Share. All of the Options will vest one-third immediately and then one third on each of the first and second anniversaries of today's date of grant, except that 1,650,000 of the Options granted to certain officers, employees and consultants will all vest immediately in recognition of such individuals work in managing the successful completion of the oversubscribed Financing.Interim CFOAs announced earlier this month, the Company will be appointing a new Chief Financial Officer ("CFO") in the coming weeks. Until such time, following the departure of Dean Larocque as CFO on May 30, 2025, Martina Blahova will serve as interim CFO.About Euro Manganese Euro Manganese is a battery materials company focused on becoming a leading producer of high-purity manganese for the electric vehicle industry. The Company is advancing development of the Chvaletice Manganese Project in the Czech Republic and an early-stage opportunity to produce battery-grade manganese products in Bécancour, Québec.The Chvaletice Project is a unique waste-to-value recycling and remediation opportunity involving reprocessing old tailings from a decommissioned mine. It is also the only sizable resource of manganese in the European Union, strategically positioning the Company to provide battery supply chains with critical raw materials to support the global shift to a circular, low-carbon economy.Euro Manganese is dual listed on the TSX-V and the ASX.Authorized for release by the CEO of Euro Manganese Inc.Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) or the ASX accepts responsibility for the adequacy or accuracy of this release. Enquiries Martina BlahovaChief Executive Officer+1 (604) 681-1010martina@mn25.caLodeRock AdvisorsNeil WeberInvestor and Media Relations - North America+1 (647) 222-0574 neil.weber@loderockadvisors.comJane Morgan Management Jane Morgan Investor and Media Relations - Australia +61 (0) 405 555 618 jm@janemorganmanagement.com.auCompany Address: #709 -700 West Pender St., Vancouver, British Columbia, Canada, V6C 1G8Website: www.mn25.caFollow us on: LinkedIn | Twitter | YouTubeClick Here to Subscribe to our mailing list for updatesForward-Looking StatementsCertain statements in this news release constitute "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws. Such statements and information involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Company, its Chvaletice Project, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. Such statements can be identified by the use of words such as "may", "would", "could", "will", "intend", "expect", "believe", "plan", "anticipate", "estimate", "scheduled", "forecast", "predict" and other similar terminology, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.Readers are cautioned not to place undue reliance on forward-looking information or statements. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements and, even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company.All forward-looking statements are made based on the Company's current beliefs including various assumptions made by the Company including that the Chvaletice Project will be developed and operate in accordance with current plans, appointment of permanent CFO, that the Company will be able to raise the financing that it requires, and that it will meet conditions of its secured credit facility. Factors that could cause actual results or events to differ materially from current expectations include, among other things: risks and uncertainties related to the Company's ability to meet the conditions of its secured credit facility, risks related to maintaining and securing necessary licenses or permits; risks related to acquisition of surface rights; inability to secure sufficient offtake agreements; the availability of acceptable financing; the potential for unknown or unexpected events to cause contractual conditions to not be satisfied; developments in EV (Electric Vehicles) battery markets and chemistries; and risks related to fluctuations in currency exchange rates, changes in laws or regulations; and regulation by various governmental agencies. For a further discussion of risks relevant to the Company, see "Risk Factors" in the Company's annual information form for the year ended September 30, 2024, available on the Company's SEDAR+ profile at www.sedarplus.ca.Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release and are expressly qualified in their entirety by this cautionary statement. Subject to applicable securities laws, the Company does not assume any obligation to update or revise the forward-looking statements contained herein to reflect events or circumstances occurring after the date of this news release.NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/253771 Copyright 2025 ACN Newswire via SeaPRwire.com.

- ASGH brought together more than 2,900 participants from 42 countries and regions- Medical Fair attracted some 13,000 buyers from 57 countries and regions- The two flagship events together resulted in over 390 deal-making sessions and more than 660 business matching meetings- Collaboration agreements were signed during the events, covering areas including patient care, diagnostic solutions, innovative medical devices, and medical imagingHONG KONG, May 28, 2025 - (ACN Newswire via SeaPRwire.com) – The fifth Asia Summit on Global Health (ASGH) and the 16th Hong Kong International Medical and Healthcare Fair (Medical Fair), both organised by the Hong Kong Trade Development Council (HKTDC), have drawn to a successful close. As flagship events of International Healthcare Week (IHW), both ASGH and the Medical Fair brought global healthcare stakeholders together, including government officials and organisations, research pioneers, investors, and business leaders. ASGH attracted over 2,900 participants from 42 countries and regions, while the Medical Fair received some 13,000 buyers from 57 countries and regions. Over 390 one-on-one deal-making sessions and more than 660 business matching meetings were arranged, facilitating over 1,000 high-quality collaborations and connections. The IHW continues to foster global exchange and cooperation, putting a spotlight on Hong Kong’s vast potential in healthcare investment and trade, and reinforcing its position as a regional leading medical hub.Dr Peter K N Lam, Chairman of the HKTDC, said: "The Asia Summit on Global Health and the Hong Kong International Medical and Healthcare Fair concluded with outstanding results driving new collaborations and investments, and injecting new momentum into the healthcare industry. The events brought together leaders across government, business, academia, and investment to tackle today’s healthcare challenges, highlighting Hong Kong’s unique advantages as an international innovation and technology hub under its ‘eight centres’ positioning, actively advancing medical technology, connecting global innovation resources, and paving the way for a healthier and more inclusive future."Over 80 industry experts shared insights on healthcare developmentThe two-day ASGH, jointly organised by the HKSAR Government and the HKTDC under the theme ‘Fostering Global Collaboration for a Shared Future’, focused on a wide spectrum of topics including public health, medical technology breakthroughs, healthy ageing and global business and investment collaboration. The event featured more than 80 speakers comprising government officials and organisations, research pioneers, investors, and business leaders from around the world, all contributing valuable insights to advance global well-being.Prof Lo Chung-mau, Secretary for Health of the HKSAR Government, delivered a keynote speech during the Plenary Session I: Shaping a More Equitable and Sustainable Health System. Other distinguished speakers, including Dr Wu Xiaobin, Vice President of China Pharmaceutical Innovation and Research Development Association; Martin Taylor, Representative to China, World Health Organization; Prof Nancy Ip, President of the Hong Kong University of Science and Technology; and Frédéric Rimattei, Special Envoy for International Affairs of the President of French University Hospitals National Association, shared their insights on tackling global healthcare challenges, offering inspiration for the international healthcare community.In Plenary Session II: Fostering Global Collaboration for a Shared Future, speakers engaged in a lively discussion on trends in global healthcare collaboration. Among them was Ambassador George Hara, Group Chairman and CEO of DEFTA Partners and former Special Advisor to the Cabinet Office of the Prime Minister of Japan, who remarked that more advanced technology and new government regulations are needed to reach a compromise between companies' profits and patients' needs.During the Dialogue with Global Pioneer in Health session, Prof John Hardy, Chair of Molecular Biology of Neurological Disease of UCL Queen Square Institute of Neurology, shared his latest research findings and advanced developments in Alzheimer's disease.The summit co-organised sessions under the overarching theme, Shaping the Future of Healthcare, with the Hong Kong University of Science and Technology for the first time. The discussion focused on the potential of AI in healthcare and how innovation could drive breakthroughs in the field. Dr Alex Ng, President of Tencent Healthcare, commented: “One uniqueness of tech companies is that they can be easily distracted by the latest thing. But you do need companies with patience and perseverance to stay in healthcare and make it work.” Prof Graham Cooke, Vice-Dean (Research) Medicine of Imperial College London, also noted that embedding patient needs into healthcare systems is critical, as many innovations fail in translation due to a lack of this focus, with universities playing a key role as innovation drivers.In Beyond ‘Healthy China 2030’: Driving Health Innovation, speakers explored opportunities in the mainland healthcare market. Marc Horn, Executive Vice President of Merck and President of Merck China, highlighted the two-phase approach of "China for China" followed by "China for the globe”, emphasising healthcare collaboration to develop advanced treatments for global benefit. Dr Zhang Lianshan, Executive Vice President of Jiangsu Hengrui Pharmaceuticals Co., Ltd., stated: "We would like to see our health innovation have realisation of its value, not only in China, but also outside of China. That is why we are talking about Globalisation, where we can achieve maximum value."With growing global attention on healthy ageing, the summit introduced a dedicated Silver Health Chapter. A highlight was the thematic session titled Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology, where Prof Jean Woo, Director of Chinese University of Hong Kong Jockey Club Institute of Ageing, Prof James L. Kirkland, Director of Cedars-Sinai’s Centre for Advanced Gerotherapeutics, and fellow experts explored both the challenges and opportunities posed by ageing populations. Prof Jean Woo highlighted that rapid population ageing is reshaping the global healthcare and socioeconomic landscape. As a city with one of the world’s longest life expectancies, Hong Kong must take early action to strengthen elderly care policies and better allocate health resources. Prof James L. Kirkland also noted that geriatricians ultimately aim to help patients with multiple illnesses reduce medication use while treating their conditions more effectively, enhancing their overall quality of life.Over 390 deal-making sessions and cooperation agreements open new global opportunitiesA key feature of the summit was the ASGH Deal-Making session, which facilitated one-on-one meetings both online and offline, aiming to connect investors and projects in the healthcare sector from around the world to promote global collaborations. Investment projects spanned pharmaceuticals, medical devices and diagnostics, smart healthcare, and community health and wellness and more than 390 one-on-one meetings were successfully arranged for angel investors, venture capitalists, corporate venture arms, private equity firms and family offices.The summit facilitated the signing of cooperation agreements, such as those between Gleneagles Hospital Hong Kong and Emerging Viral Diagnostics, and a tripartite collaboration with PanopticAI and SmartCare, HKSH Medical Group and United Imaging Healthcare, China Resources Guangdong Pharmaceuticals and Hong Kong Medtech Association, Hugobiotech and Bridgeway Healthcare Technology, Canossa Hospital and KA Imaging, and others. These agreements covered diverse healthcare areas, including patient care, diagnostic solutions, innovative medical devices, medical imaging and more. Under the tripartite collaboration agreement between Gleneagles Hospital Hong Kong, PanopticAI, and SmartCare, the integration of PanopticAI’s camera-based vital signs monitoring technology and SmartCare’s patient-centered consultation platform will be implemented into Gleneagles clinic in the future.In addition to its discussion sessions, the summit also featured the ASGH Business Hub, showcasing more than 170 innovative technology companies related to the healthcare industry from 13 countries and regions, including the mainland (Shanghai and Xiamen), Australia, and Thailand, presenting projects and solutions across key areas such as medical innovation, smart healthcare, AI, big data, telemedicine, and cybersecurity. Zhong Wei, Co-founder of Mitrassist Lifesciences, joined the Shanghai Pavilion and said that ASGH helped them bring non-invasive medical monitoring technologies to Southeast Asia, Africa, and other Belt and Road Initiative countries.Medical Fair Drives Industry Innovation and Fosters Business CollaborationThe Medical Fair, organised by the HKTDC and co-organised by the Hong Kong MedTech Association, was held alongside ASGH. The Association—formerly known as the Hong Kong Medical and Healthcare Device Industries Association—held a renaming ceremony during the fair, showcasing the deep integration of medical technology and the industry.The fair brought together some 300 exhibitors from 13 countries and regions, featuring first-time pavilions from the United Kingdom, Thailand and Israel, along with debut exhibitors from Singapore, Germany, Italy and Luxembourg. In addition, seven local universities, over 30 innovative technology companies at the Hong Kong Science and Technology Parks pavilion, and more than 20 medical enterprises brought by the Hong Kong MedTech Association participated. The Hong Kong Council of Social Service also participated in the fair for the first time. Under the theme Innovations Boosting Smart Health Experience, the exhibition spotlighted three major areas: MedTech, GeronTech and green solutions, with many exhibits featuring applications of AI.Many exhibitors and buyers successfully expanded their networks and forged new partnerships at the exhibition. Among them was Hong Kong exhibitor Eieling Technology, a company founded to commercialise research outcomes from the Hong Kong Polytechnic University. The firm showcased its non-invasive liver examination technology, which utilises transient elastography technology. Co-founder and CEO Xiaojia Jia noted that only about four companies worldwide possess this technology, making it a major draw for buyers. "During the exhibition, we received intention orders worth several million Hong Kong dollars from mainland China, Hong Kong, Indonesia, and Thailand, involving around ten devices. This is our third year participating, and we've observed a significant rise in buyers' professionalism during our discussions. We look forward to exhibiting again next year."Karel Lee, CEO of Neoneco from Korea, sourced innovative medical products at the fair with a minimum budget of USD100,000 and he has already identified RhinoCare, an exhibitor from the Israeli pavilion, for its nasal decongestion device, and is also interested in a medical examination device from a Hong Kong exhibitor. Lee stated, "The exhibition allows us to meet with exhibitors face-to-face, build trust, and accelerate the decision-making process. The HKTDC’s Click2Match platform also facilitated efficient business matching. I have already connected with ten exhibitors, and another twenty reached out to me after learning about my sourcing needs. This is one of Asia's premium medical sourcing events, and we will definitely return next year."Beyond business deals, insightful forums were arranged during the Medical Fair to give inspiration to industry buyers. These included The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area, The MedTech Nexus of the Greater Bay Area, co-organised with the Hong Kong MedTech Association, and Fostering Silver Economy, Leading Quality Elderly & Rehabilitation Care Practices, co-organised with the HKCSS. These forums attracted a strong attendance and offered valuable insights into healthcare. Selected sessions are available for replay on the Fair’s website for extended engagement.This year’s Fair continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing (hktdc.com Sourcing). Click2Match will remain available until 4 June.WebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enHong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/enPhoto download: https://bit.ly/4kbr9NcThe fifth Asia Summit on Global Health was attended by over 2,900 participants from 42 countries and regionsProf Lo Chung-mau, Secretary for Health of the HKSAR Government, delivered a keynote speech on the first day during the Plenary Session I: Shaping a More Equitable and Sustainable Health SystemProf John Hardy, Chair of Molecular Biology of Neurological Disease at UCL Queen Square Institute of Neurology. As an internationally renowned neurogeneticist, Prof John Hardy has been awarded the Brain Prize for "groundbreaking research on the basis of Alzheimer's disease" and is known as the “father of Alzheimer’s disease genetic studies”. He shared his latest research findings and advanced developments during the Dialogue with Global Pioneer in Health sessionWith growing global attention on healthy ageing, the summit introduced a dedicated Silver Health Chapter for the first time. A highlight was the thematic session titled Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology, where Prof Jean Woo, Director of Chinese University of Hong Kong Jockey Club Institute of Ageing (far left), and fellow experts explore the challenges and opportunities posed by ageing populationsIn addition to its discussion sessions, the summit also featured the ASGH Business Hub, showcasing more than 170 innovative solutions from the healthcare industry across 13 countries and regionsASGH Deal-making facilitated over 390 one-on-one meetings(Front row from the left) Dr Kyle Wong, Chief Executive Officer and Co-founder of PanopticAI Limited, Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong, and Dr Justin Cheng, Chief Executive Officer and Co-founder of SmartCare Technology Co Limited signed a tripartite cooperation agreement witnessed by (back row from the left) Prof Nancy Ip, President of The Hong Kong University of Science and Technology, Dr Prem Kumar Nair, Group Chief Executive Officer of IHH Healthcare and Patrick Lau, Deputy Executive Director of Hong Kong Trade Development CouncilThe 16th Hong Kong International Medical and Healthcare Fair attracted some 13,000 buyers from 57 countries and regions who visited the fair for sourcing and procurementThe Hong Kong MedTech Association had a delegation of over 20 companies participating in the fair, attracting strong interest from buyers who engaged with exhibitors to explore business opportunitiesThe United Kingdom pavilion, participating in the Medical Fair for the first time, promoted innovative medical devices, solutions and services from multiple companies at the fairAn expert from the Greater Bay Area Center for Medical Device Evaluation and Inspection of the National Medical Products Administration; Eva Wong, Senior Electronics Engineer, Medical Device Division of Department of Health (pictured); along with SGS-CSTC Standards Technical Services Co., Ltd.’s expert, shared insights at The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area forumCo-organised by the Hong Kong Council of Social Service, the Fostering Silver Economy, Leading Quality Elderly & Rehabilitation Care Practices forum drew a strong turnout from industry professionalsMedia enquiriesFor enquiries, please contact Yuan Tung Financial Relations Limited:Louise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Asia Summit on Global HealthSharon HaTel: (852) 2584 4575Email: sharon.mt.ha@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgHong Kong International Medical and Healthcare FairKelly ShekTel: (852) 2584 4537Email: kelly.yt.shek@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - May 27, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce the following internal GMG run engine test results when G® Lubricant was added to a Caterpillar 22 kVA diesel engine run at an 80% Load. Test results show a 10% increase in energy efficiency (kwh/litres), and also a 33% reduction in harmful diesel engine exhaust particulate matter emissions, when three doses of G® Lubricant, with a maximum graphene dosage of 0.03%, was added to the standard diesel engine oil.It is noted that the test engine was not operating optimally before G® Lubricant was added - the engine was overheating at long runs of sustained high loads. As a result, after the initial dose of G® Lubricant was added, an additional two dosages of G® Lubricant were used to hopefully bring the engine into a more stable operating regime, an outcome that was generally achieved.Figure 1To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/253490_gmg_image.jpgBuy Now at: www.G-Lubricant.com Figure 2 and 3 show the table and graph distribution of engine efficiency of the various dosages of G® Lubricant versus the baseline.Baseline Diesel Engine OilEngine Efficiency (kwh/litres)G® Lubricant (0.01%)Engine Efficiency (kwh/litres)G® Lubricant (0.02%)Engine Efficiency (kwh/litres)G® Lubricant (0.03%)Engine Efficiency (kwh/litres)3.043.36 (10% increase)3.35 (10% increase)3.36 (10% increase)Figure 2: Engine Efficiency Performance Increase from G® LubricantFigure 3: % Distribution of Fuel Efficiency Relative to BaselineTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/253490_d626526a342c2ac9_005full.jpgFigures 4 and 5 show the table and graph distribution of diesel engine particulate matter emissions of the various dosages of G® Lubricant versus the baseline.Baseline Diesel Engine OilParticulate Matter (ppm)G® Lubricant (0.01%)Particulate Matter(ppm)G® Lubricant (0.02%)Particulate Matter (ppm)G® Lubricant (0.03%)Particulate Matter (ppm)20.9715.56 (26% reduction)14.55 (31% reduction)13.97 (33% reduction)Figure 4: Engine Emission Particulate Matter Reduction from G® LubricantFigure 5: % Distribution of Particulate Matter in Emissions Relative to BaselineTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/253490_d626526a342c2ac9_006full.jpgFigure 6 shows the exhaust emissions of the diesel engine at various dosages of G® Lubricant, versus the baseline which shows similar levels as the baseline test runs. More testing is being done to get more detail on the impact of G® Lubricant across engine emissions. % O2ppm COppm NO% CO2°C FTppm NOxppm NO2Baseline (DEO)7.8151.5359.69.830.0362.22.7DEO + 1% G® Lubricant7.5161.3383.510.028.1386.73.3DEO + 2% G® Lubricant7.5170.6377.010.027.6379.82.8DEO + 3% G® Lubricant7.4184.8388.710.128.4391.42.7Figure 6: Emissions Data for G® Lubricant Relative to BaselineDetailed Equipment and Process for Testing G® LubricantThe following describes the equipment used and the process followed by the Company in demonstrating the fuel saving demonstration of the G® Lubricant in the diesel engine generator:The same testing equipment, data systems and processes were used which was verified by the University of Queensland and detailed in GMG's previous press release on the 25th February, https://graphenemg.com/gmg-unveils-g-lubricant-engine-performance-testing-results-a-transformative-graphene-energy-saving-solution-for-the-multi-trillion-dollar-global-liquid-fuel-industry/GMG also added the following testing equipment to the testing program:Testo 340 Diesel Kit 2 engine emissions test kit which was newly calibrated by the third-party supplier.PDSA DPM-RT-2 particulate matter test unit which was newly calibrated by the third-party supplier.A 22kVA Caterpillar diesel engine generator (with 1,959 hours of run time) was setup in the GMG Richlands warehouse.The generator was connected to a 40-kW power load bank which consumed the energy produced by the generator and created the load and a 500-litre self-contained fuel tank.Two calibrated flow sensors were connected (inflow and return/outflow) to the fuel lines and to a data logger which recorded the fuel consumption.An Energy Analyzer was used to log and track energy produced by the generator.Tests were conducted on 80% loads of the engine from the 40-kW power load bank - 22 kW.A baseline to record diesel fuel consumption under normal engine oil and operating conditions was completed with newly changed recommended premium diesel engine oil and a new oil filter. This oil change was carried out by a professional engine maintenance service company.The engine was run at 80% load and the baseline and G® Lubricant data set used for the analytics is when the maximum ambient temperature for the day was less than 33 degrees Celsius and relative humidity was between 50% and 80% with no rain. Fuel consumption for diesel engines changes when operating in rain or very high humidity or temperatures, so the fuel consumption data baseline and G® Lubricant engine oil additive performance testing were excluded for these times.Only steady state data was used and so any variance or anomalous data seen in either baseline or G® Lubricant datasets were removed from the analytics. Data sets were grouped into minute blocks.Once the baseline fuel tests were completed, G® Lubricant with approximately 1:100 concentration was mixed at approximately 1% ratio by weight into the existing engine oil. This was done another 2 times. The end ratio of GMG's Graphene to the diesel engine oil was approximately 3:10,000 by weight.GMG's Managing Director and CEO, Craig Nicol, commented: "G® Lubricant is not only increasing fuel efficiency it is also reducing particulate matter - which is amazing to see - we will need to do more tests to see what the long-term performance is for this."GMG is continuing to conduct more tests to determine the total performance regime of the G® Lubricant. These performance tests will be announced as the information becomes available.GMG's Chairman and Director, Jack Perkowski, commented: "Fantastic news - G® Lubricant testing data are exciting - well done to the team - showing great promise as a way to reduce fuel costs and emissions across the multi-trillion dollar liquid fuels industry."About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking Statements This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, the potential of G® Lubricant to optimize efficiency and power for stationary or mobile engines, the potential of G® Lubricant to reshape the future of the global liquid fuels industry, GMG's intention to commercialise and market G® Lubricant, the progress of the Company's patent applications, the potential market for G® Lubricant and the potential revenue available for G® Lubricant.Such forward-looking statements are based on a number of assumptions of management, including, without limitation that G® Lubricant has the potential to optimize efficiency and power for stationary or mobile engines, that G® Lubricant has the potential to reshape the future of the global liquid fuels industry, that GMG will commercialize and market G® Lubricant, that the Company's patent applications will progress as anticipated, and that the potential market and revenue available for G® Lubricant will be as currently forecasted. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that G® Lubricant will not offer an innovative solution that optimizes efficiency and power for stationary or mobile engines, that G® Lubricant will not reshape the future of the global liquid fuels industry, that GMG will commercialize and market G® Lubricant as anticipated, that the Company's patent applications will not progress as currently anticipated, that the potential market and revenue available for the G® Lubricant product is not as currently calculated, risks relating to the extent and duration of the conflict in Eastern Europe and its impact on global markets, the volatility of global capital markets, political instability, the failure of the Company to obtain regulatory approvals, attract and retain skilled personnel, unexpected development and production challenges, unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253490 Copyright 2025 ACN Newswire via SeaPRwire.com.